Ann: Poster Presentation at 2022 MDA Conference, page-66

Data is needed... unfortunately, the industry we're in we have to be patient!

I am trying to understand the timelines better and went over updates outside the core Phase IIb/III pivotal trial in Europe - results due mid-year 2023.

Other developments that make ANP not just a DMD drug play...

1. Feb this year - 'Having achieved positive results in the DMD mdx animal model, antisense inhibition of CD49d is now to be assessed in a mouse model of another inflammatory muscle disease, where there are similar immune mediated inflammatory features to the mdx model.

While the Company has filed patents to seek protection for the use of ATL1102 in this new indication, the Company has not named the indication as further important intellectual property protection could be generated through the successful conduct of the study program at the MCRI. ANP can, however, advise that the new inflammatory muscle disease indication being studied is a rare muscle disease that effects both children and adults with no effective marketed therapy, no disease modifying agents in advanced development and where ATL1102’s observed immunomodulatory activity would be suggestive of potential treatment benefits. Dosing has now commenced in the first phase (acute setting) of this development program where the antisense inhibition of CD49d target effects in the muscle will be assessed. Results from this first phase of the program are anticipated in 2Q’CY22.'

2. March 2022 - Long covid collaboration - The first results from the testing of Long Neuro COVID-19 patient samples are anticipated in mid-2022.

3. ATL1102 has completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS).

4. A second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.

Would love Sue Turner and ANP to be more visual with the communications. Keep it simple - show the drug - timeline to next announcement / result and the impacts of the expected announcements.

Buffet did say - he buys and doesn't worry about the share price (doesn't look at the daily price) as you should be confident in the long term value of the asset!